Background: The adjunctive use of connective tissue grafts (CTGs) in the periodontal regeneration of intrabony defects has been proposed to prevent or limit postoperative gingival recession. However, there is limited evidence regarding the long-term clinical performance of this approach.
Methods: This article presents the five-year follow-up outcomes of a combination therapy using CTG, bone substitutes, and biologics for the treatment of deep intrabony defects associated with gingival recession. Twelve healthy, non-smoking patients with 12 deep intrabony defects participated in the study. These patients had a mean clinical attachment loss (CAL) of 9.9 ± 2.1 mm, a mean probing depth (PPD) of 7.8 ± 1.5 mm, and a mean buccal recession (REC) of 2.3 ± 1.8 mm at baseline, before= undergoing the described treatment regimen.
Results: After five years, the mean clinical attachment level (CAL) gain was 5.7 ± 3.2 mm (p < 0.001), the mean reduction in probing pocket depth (PPD) was 5.1 ± 1.6 mm (p < 0.001), and the mean reduction in recession (REC) was 1.2 ± 2.1 mm (p = 0.07) Ninety-one percent of sites achieved CAL gain of ≥3 mm and PPD ≤ 4 mm. Compared to baseline, 7 out of 12 sites showed a REC reduction of ≥1 mm, while three sites remained stable, and two sites experienced an increase in gingival recession depth of 1 and 2 mm respectively.
Conclusion: Within the limitations of this case series, periodontal regenerative therapy incorporating the adjunctive use of CTG showed to be effective for treating deep non-contained periodontal intrabony defects and respectively stabilize or slightly improve the gingival margin over five years.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.11607/prd.7510 | DOI Listing |
Background: The adjunctive use of connective tissue grafts (CTGs) in the periodontal regeneration of intrabony defects has been proposed to prevent or limit postoperative gingival recession. However, there is limited evidence regarding the long-term clinical performance of this approach.
Methods: This article presents the five-year follow-up outcomes of a combination therapy using CTG, bone substitutes, and biologics for the treatment of deep intrabony defects associated with gingival recession.
Clin Adv Periodontics
December 2024
Department of Periodontal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
Background: Recombinant human fibroblast growth factor-2 (rhFGF-2) has been shown to effectively promote the formation of new periodontal tissues, and its efficacy has been demonstrated in clinical settings. Moreover, the clinical and radiographic outcomes in the treatment of periodontal infrabony defects can be improved by using rhFGF-2 in combination with a bone substitute. Here, we present a case of four-wall bone defect in a tooth treated by combination regenerative therapy using rhFGF-2 and beta-tricalcium phosphate (β-TCP).
View Article and Find Full Text PDFJ Evid Based Dent Pract
December 2024
Assistant Professor, Department of Restorative Dentistry, Maurice H. Kornberg School of Dentistry, Temple University, Philadelphia, PA.
Background: The objective of this systematic review is to assess the clinical outcomes of intrabony and furcation defects treated using a regenerative approach with calcium phosphate (CP) grafts combined plus guided tissue regeneration (GTR) membrane in comparison to open flap debridement (OFD).
Method: A review protocol was created under PRISMA checklist to find randomized clinical trials (RCTs) in English that compared CPs plus GTR with OFD in humans with intrabony and/or furcation defects. Both electronic and manual searches were conducted.
Ther Adv Chronic Dis
November 2024
Division of Periodontology, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, 188 Longwood Avenue, Boston, MA 02115, USA.
Growth factors were introduced to increase predictability in periodontal regeneration and have since been widely applied in dentistry. This narrative review article highlights histological and latest findings of recombinant human platelet-derived growth factor-BB (rhPDGF-BB) and recombinant human fibroblast growth factor-2 (rhFGF-2) for periodontal regeneration. rhPDGF-BB enhances the proliferation and chemotaxis of periodontal ligament and alveolar bone cells.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!